BusinessCRISPR Therapeutics Announces European Patent for CRISPR/Cas Gene EditingBy Nasdaq OMXMar 28, 2017, 12:01 PM UTC
BusinessCRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement With MaxCyteBy Nasdaq OMXMar 14, 2017, 11:00 AM UTC
BusinessCRISPR Therapeutics to Present at the Annual Barclays Global Healthcare ConferenceBy Nasdaq OMXMar 2, 2017, 9:30 PM UTC
BusinessCRISPR Therapeutics Announces the Appointment of Jon Terrett, Ph.D. to Head of Immuno-Oncology Research and TranslationBy Nasdaq OMXFeb 28, 2017, 1:01 PM UTC
BusinessAbeona Therapeutics to Present at the 2017 RBC Capital Markets Global Healthcare Conference and 3rd Annual CRISPR CongressBy Nasdaq OMXFeb 21, 2017, 12:48 PM UTC
BusinessEditas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare ConferenceBy Nasdaq OMXJan 9, 2017, 1:01 PM UTC
BusinessCRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Global Agreement on the Foundational Intellectual Property for CRISPR/Cas9 Gene Editing TechnologyBy Nasdaq OMXDec 16, 2016, 1:00 PM UTC
BusinessCRISPR Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare ConferenceBy Nasdaq OMXNov 22, 2016, 1:00 PM UTC
